Impact of the Pentavalent Meningococcal Conjugate Vaccine(NmCV-5) Targeting Serogroups A,C,Y,W, and X on the Sub-Saharan Africa Region

Meningococcal disease poses a considerable public health burden in sub-Saharan Africa (SSA), particularly in the "meningitis belt". Although the rollout of the serogroup A meningococcal vaccine (MenAfriVac) has effectively contributed to a significant reduction in the incidence of group A meningitis, serogroups C, W, Y, and X are experiencing rising infection rates, highlighting the urgent need for new vaccines to address the threat posed by non-serogroup A Neisseria meningitidis. Considering this, Serum Institute of India Pvt Ltd., in partnership with PATH, developed a pentavalent conjugate vaccine (NmCV-5) containing capsular polysaccharides of meningococcal serogroups: A, C, W, X and Y, conjugated to a protein carrier, tetanus toxoid. In this paper, the epidemic trend of meningococcal and the development of NmCV-5 vaccine in SSA were analyzed by literature review. It has been shown that the NmCV-5 vaccine demonstrated good safety and immunogenicity against all serogars in clinical trials, especially significant protection against Neisseria meningitidis serogroup X. The single-dose schedule of the vaccine also improves roll-out feasibility in resource-limited Settings. However, the rollout of the vaccine still faces challenges such as poor infrastructure and insufficient public awareness.